Opexa Therapeutics to Present at Cleveland Clinic’s 12th Annual Medical Innovation Summit

October 20, 2014

THE WOODLANDS,
Texas–(BUSINESS WIRE)– Opexa
Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing
personalized immunotherapies for autoimmune disorders, including multiple
sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K.
Warma, the Company’s President and Chief Executive Officer, has been invited to
present at the Cleveland Clinic’s 12^th Annual Medical Innovation
Summit, taking place October 26-29, 2014, in Cleveland, Ohio.


Opexa’s
presentation is part of the Ground Waves showcase and will take place on
Wednesday, October 29 at 9:15 am ET at the Cleveland Convention Center in Room
26.
Cleveland
Clinic’s 12^th Annual
Medical Innovation Summit will bring together more than 1,500
executives, investors, entrepreneurs and clinicians to examine the latest
innovations in cancer treatment and personalized medicine. The Summit will
feature a large variety of healthcare stakeholders from executives in
pharmaceuticals, diagnostics and devices to information technology leaders,
payers, investors, and entrepreneurs who will discuss the most promising
market-ready therapies. The Summit, titled, “Now, it’s Personal” will
take a deep look at how targeted, personalized therapies are changing the game
in medicine.
Ground Waves is a two-day showcase
taking place as part of the Medical Innovation Summit that will present a wide
array of companies making waves and looking to shake up the status quo in
cancer treatment and personalized medicine.




About Opexa
Opexa is a
biopharmaceutical company developing personalized immunotherapies with the
potential to treat major illnesses, including multiple sclerosis (MS) as well
as other autoimmune diseases such as neuromyelitis optica (NMO). These
therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading
therapy candidate, Tcelna^®, is a personalized T-cell immunotherapy
that is in a Phase IIb clinical development program (the Abili-T trial) for the
treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated
from the patient’s peripheral blood, expanded ex vivo, and reintroduced
into the patients via subcutaneous injections. This process triggers a potent
immune response against specific subsets of autoreactive T-cells known to
attack myelin. Opexa’s mission is to lead the field of Precision Immunotherapy®
by aligning the interests of patients, employees and shareholders.

For more
information visit the Opexa Therapeutics website at www.opexatherapeutics.com. 

Source: Opexa
Therapeutics, Inc.

View this news
release online at:
http://www.businesswire.com/news/home/20141020005780/en